Zobrazeno 1 - 10
of 36
pro vyhledávání: '"A. V. Michenko"'
Management of patients at high risk of developing skin melanoma: organizational and clinical aspects
Publikováno v:
Медицинский совет, Vol 0, Iss 8, Pp 21-26 (2021)
Early diagnosis of skin melanoma is one of the most reliable ways to improve the prognosis for the life of patients with this tumor. Organization of medical care for patients with a high risk of developing melanoma, together with the use of non-invas
Externí odkaz:
https://doaj.org/article/2aece932df70499b931a396922187e67
Autor:
A. V. Michenko, L. S. Kruglova, E. A. Shatokhina, I. B. Kononenko, A. S. Polonskaya, D. V. Romanov
Publikováno v:
Онкогематология, Vol 16, Iss 4 (2021)
Therapy with epidermal growth factor receptor (EGFR) inhibitors is inevitably accompanied by the phenomena of dermatological toxicity. Being, on the one hand, a favorable prognostic factor for the effectiveness of anticancer therapy, these adverse ev
Externí odkaz:
https://doaj.org/article/eba763607e334152b166c66c5c8a1320
Autor:
Aleksandra S. Polonskaia, Anna V. Michenko, Larisa S. Kruglova, Evgeniya A. Shatokhina, Andrey N. Lvov
Publikováno v:
Consilium Medicum, Vol 25, Iss 6, Pp 400-405 (2023)
Modern antitumor therapy includes novel targeted and immunotherapeutic options specifically targeting tumor targets. However, many of these targets are also expressed in the constantly proliferating epidermis of the skin, leading to derangement of pr
Externí odkaz:
https://doaj.org/article/74b86a386ced4439a74027ce9cb9cc87
Publikováno v:
Consilium Medicum, Vol 24, Iss 8, Pp 504-510 (2022)
Pruritus is one of the subjective sensations that significantly reduces the quality of life of patients. In patients with malignancies, itch can be caused by different universal or specific pathophysiological factors. This article discusses disorders
Externí odkaz:
https://doaj.org/article/4bf5002d16ae41c4932be44116476a02
Autor:
Nadezhda V. Maksimova, Anna V. Michenko, Olga A. Krasilnikova, Ilya D. Klabukov, Igor Yu. Gadaev, Michael E. Krasheninnikov, Pavel A. Belkov, Aleksey V. Lyundup
Publikováno v:
BioImpacts, Vol 12, Iss 1, Pp 51-55 (2022)
Introduction: Mesenchymal stromal cells (MSCs) administration is an effective option for the treatment of diabetic foot ulcers (DFUs). However, to date, studies assessing long-term outcomes and evaluating skin parameters after cell-based therapy are
Externí odkaz:
https://doaj.org/article/217963ca477b46948d986a20e5494f8b
Publikováno v:
Medical alphabet. :35-40
Therapy of moderate-to-severe atopic dermatitis (AD) is associated with a number of diffculties due to the propensity of the disease to a chronic relapsing course, the tendency to develop in childhood and young age. However, a new selective JAK1 inhi
Publikováno v:
Medical alphabet. :92-95
Basal cell skin cancer most often requires differential diagnosis in patients with neoplastic skin lesions, both pigmented and non-pigmented. The cytological examination is simple to perform and is widely used for the initial examination of patients
Publikováno v:
Medical alphabet. :7-11
According to the current concepts, pathogenesis of acne includes signifcant morphological and functional changes and hypercolonization of C. acnes of the sebaceous hair follicle. But most important input into pathogenesis of acne gives permanent in
Autor:
Pavel A. Belkov, Olga A. Krasilnikova, Michael E. Krasheninnikov, Igor Yu. Gadaev, Anna V. Michenko, Nadezhda V. Maksimova, Ilya D. Klabukov, Aleksey V. Lyundup
Publikováno v:
BioImpacts, Vol 12, Iss 1, Pp 51-55 (2022)
BioImpacts : BI
BioImpacts : BI
Introduction: Mesenchymal stromal cells (MSCs) administration is an effective option for the treatment of diabetic foot ulcers (DFUs). However, to date, studies assessing long-term outcomes and evaluating skin parameters after cell-based therapy are
Autor:
Irena L. Shlivko, Oxana E. Garanina, Elena V. Artamonova, Inna P. Ganshina, Liudmila G. Zhukova, Irina A. Koroleva, Anna V. Michenko, Tatiana Yu. Semiglazova, Daria A. Filonenko
Publikováno v:
Современная онкология, Vol 23, Iss 4, Pp 572-576 (2021)
The consensus on the prevention and correction of rash in patients with HR+ HER2- metastatic breast cancer treated with alpelisib was developed by the experts of the Russian Society of Clinical Oncology and dermatovenerologists. PIK3CA mutation is a